Literature DB >> 25203722

Evaluation of a multimodal resin for selective capture of CHO-derived monoclonal antibodies directly from harvested cell culture fluid.

Kimberly A Kaleas1, Margaret Tripodi2, Scott Revelli2, Vikas Sharma2, Shelly A Pizarro2.   

Abstract

This proof-of-concept study examines the applicability of using multimodal chromatography to selectively capture recombinantly produced monoclonal antibodies (mAb) directly from harvested mammalian cell culture fluid (HCCF) with minimal optimization. Capto MMC is a multimodal resin that contains a ligand with the potential to participate in ionic, hydrophobic, and hydrogen boding interactions with proteins and is coupled to a highly cross-linked agarose bead matrix. Twelve mAb HCCF feedstocks were examined for dynamic binding capacity (DBC) and then two representative feedstocks were selected to develop a systematic approach for elution buffer development. A range of dynamic binding capacities was observed for 10 feedstocks (24-53g/L) and two feedstocks had poor binding properties (<10g/L) despite load conditioning towards a more favorable pH. Analysis of the DBC versus molecular properties showed that the mAb-ligand binding interaction was predominantly charge based. Four separate elution strategies were identified to selectively recover the mAb and could be applied with minimal optimization to other mAb feedstocks. Downstream processing of the Capto MMC pools showed that it is feasible to produce material with comparable purity to a process with affinity capture after two chromatography steps.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Capto MMC; Mammalian cell culture fluid; Monoclonal antibody; Multimodal chromatography; Selective capture

Mesh:

Substances:

Year:  2014        PMID: 25203722     DOI: 10.1016/j.jchromb.2014.08.026

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.

Authors:  Kristell Lebozec; Martine Jandrot-Perrus; Gilles Avenard; Olivier Favre-Bulle; Philippe Billiald
Journal:  MAbs       Date:  2017-06-09       Impact factor: 5.857

2.  Application of enhanced electronegative multimodal chromatography as the primary capture step for immunoglobulin G purification.

Authors:  Yanli Wang; Quan Chen; Mo Xian; Rui Nian; Fei Xu
Journal:  AMB Express       Date:  2018-06-01       Impact factor: 3.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.